Compare STRIDES PHARMA SCIENCE with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ASTRAZENECA PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ASTRAZENECA PHARMA STRIDES PHARMA SCIENCE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 13.9 78.2 17.8% View Chart
P/BV x 0.8 22.0 3.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ASTRAZENECA PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,278 89.7%   
Low Rs642883 72.7%   
Sales per share (Unadj.) Rs317.2228.4 138.9%  
Earnings per share (Unadj.) Rs7.810.4 75.7%  
Cash flow per share (Unadj.) Rs25.116.3 154.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.398.8 277.7%  
Shares outstanding (eoy) m89.5025.00 358.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.7 59.6%   
Avg P/E ratio x114.0104.2 109.4%  
P/CF ratio (eoy) x35.766.4 53.7%  
Price / Book Value ratio x3.310.9 29.8%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05827,008 296.4%   
No. of employees `0002.51.4 184.9%   
Total wages/salary Rs m4,3411,535 282.7%   
Avg. sales/employee Rs Th11,325.84,210.9 269.0%   
Avg. wages/employee Rs Th1,731.41,132.2 152.9%   
Avg. net profit/employee Rs Th280.1191.1 146.6%   
INCOME DATA
Net Sales Rs m28,3945,710 497.3%  
Other income Rs m941123 767.8%   
Total revenues Rs m29,3345,833 502.9%   
Gross profit Rs m3,965463 856.6%  
Depreciation Rs m1,540147 1,045.0%   
Interest Rs m1,9620-   
Profit before tax Rs m1,403438 320.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97179 54.4%   
Profit after tax Rs m702259 271.0%  
Gross profit margin %14.08.1 172.3%  
Effective tax rate %6.940.8 17.0%   
Net profit margin %2.54.5 54.5%  
BALANCE SHEET DATA
Current assets Rs m24,8363,209 773.9%   
Current liabilities Rs m18,9932,070 917.8%   
Net working cap to sales %20.620.0 103.1%  
Current ratio x1.31.6 84.3%  
Inventory Days Days7172 98.1%  
Debtors Days Days11335 324.7%  
Net fixed assets Rs m34,289790 4,338.7%   
Share capital Rs m89550 1,790.0%   
"Free" reserves Rs m23,6512,419 977.6%   
Net worth Rs m24,5462,469 994.0%   
Long term debt Rs m15,5130-   
Total assets Rs m65,4374,605 1,420.9%  
Interest coverage x1.7NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.2 35.0%   
Return on assets %4.15.6 72.4%  
Return on equity %2.910.5 27.3%  
Return on capital %6.917.7 38.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,697300 5,240.2%   
Fx outflow Rs m7352,015 36.5%   
Net fx Rs m14,962-1,715 -872.2%   
CASH FLOW
From Operations Rs m1,87188 2,128.2%  
From Investments Rs m5,826-94 -6,224.3%  
From Financial Activity Rs m-10,157NA-  
Net Cashflow Rs m-2,615-6 45,875.3%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 0.3 12,600.0%  
FIIs % 8.6 15.7 54.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 9.1 284.6%  
Shareholders   56,241 12,856 437.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 14, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS